--- title: "HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations" type: "News" locale: "en" url: "https://longbridge.com/en/news/286197909.md" description: "HBM Holdings Ltd. announced that its independent non-executive director, Dr. Xiaoping Ye, is under investigation by the China Securities Regulatory Commission for alleged information disclosure violations. The company stated that Dr. Ye does not engage in daily management and will cooperate with regulators. HBM's operations are reported to be normal, with no expected impact from the probe. Shareholders are advised to exercise caution during the inquiry. The latest analyst rating for HBM stock is a Buy, with a price target of HK$17.00." datetime: "2026-05-13T04:40:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286197909.md) - [en](https://longbridge.com/en/news/286197909.md) - [zh-HK](https://longbridge.com/zh-HK/news/286197909.md) --- # HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks HBM Holdings Ltd. ( (HK:2142) ) has shared an announcement. HBM Holdings Ltd. disclosed that independent non-executive director Dr. Xiaoping Ye is under investigation by the China Securities Regulatory Commission over alleged violations related to information disclosure on shareholding changes in Hangzhou Tigermed Consulting Co., Ltd. Dr. Ye, who does not participate in HBM’s day-to-day management, has pledged to cooperate with regulators and comply with disclosure rules. The board said HBM’s operations remain normal and does not expect the probe to affect the group’s business, while promising further updates as the investigation progresses. Shareholders and potential investors have been urged to exercise caution when dealing in the company’s shares amid the ongoing regulatory inquiry. The most recent analyst rating on (HK:2142) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page. **More about HBM Holdings Ltd.** HBM Holdings Ltd. is a Cayman Islands–incorporated company listed in Hong Kong, operating through a group structure. Its board consists of executive and independent non-executive directors, with oversight of the company’s strategic direction and compliance with Hong Kong listing and securities regulations. **Average Trading Volume:** 3,391,318 **Technical Sentiment Signal:** Buy **Current Market Cap:** HK$11.72B ### Related Stocks - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [02142.HK](https://longbridge.com/en/quote/02142.HK.md) - [300347.CN](https://longbridge.com/en/quote/300347.CN.md) - [03347.HK](https://longbridge.com/en/quote/03347.HK.md) ## Related News & Research - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md) - [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md) - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md) - [Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds](https://longbridge.com/en/news/286487023.md)